Description
Nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma
Article: Nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart
